Total Funding
62
43
Total FundingPost-IPO Equity raised
Growth Score 62 in past quarter
-8 pts
Heat Score 43 in past quarter
-2 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
125697
Predictive Oncology is working with the pharmaceutical, diagnostic, and biotech industries to develop customizable assessment methods.
- J. Melville Engle: CEO & Chairman of the Board
- Raymond Vennare: Chief Executive OfficerPast Role: ThermalTherapeuticSystems, Co-Founder, President and CEO
About the Company
Predictive Oncology operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech.
Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development
of new targeted therapies in collaborations with pharmaceutical companies.